Free Trial
NASDAQ:XBIO

Xenetic Biosciences Q4 2023 Earnings Report

Xenetic Biosciences logo
$2.89 +0.07 (+2.34%)
Closing price 08/22/2025 03:19 PM Eastern
Extended Trading
$2.91 +0.02 (+0.83%)
As of 08/22/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenetic Biosciences EPS Results

Actual EPS
-$0.77
Consensus EPS
-$0.87
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Xenetic Biosciences Revenue Results

Actual Revenue
$0.67 million
Expected Revenue
$0.68 million
Beat/Miss
Missed by -$10.00 thousand
YoY Revenue Growth
N/A

Xenetic Biosciences Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Friday, March 22, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Xenetic Biosciences' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Xenetic Biosciences Earnings Headlines

Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update
HC Wainwright Issues Positive Estimate for XBIO Earnings
This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

View Xenetic Biosciences Profile

More Earnings Resources from MarketBeat